Wegovy Doses: A Complete Clinical Reference

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide dosing and protocol hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Last March, a 44-year-old teacher named Rebecca in Tulsa messaged her clinician at 11 p.m. on a Tuesday. She'd been on compounded semaglutide for nine weeks, had just stepped up to 1.0 mg, and was staring at the ceiling wondering whether the nausea rolling through her was normal or a sign she should have stayed at 0.5 mg longer. "I keep Googling 'Wegovy doses' and getting the same five-bullet list," she wrote. "Nobody explains why it's that way." Her clinician responded the next morning with a longer explanation than she expected, and Rebecca's message is roughly the reason this article exists.

This guide sits inside the broader Compounded Semaglutide Dosing and Protocols cluster, which is part of the compounded semaglutide pillar guide.

What You'll Actually Find Here (and What You Won't)

This is a clinical reference for Wegovy doses in the context of compounded semaglutide therapy as it stands in 2026. It draws on the published trial program for semaglutide as a molecule, including SUSTAIN, STEP-1, STEP-3, STEP-4, LEADER, and SELECT. It also draws on clinical observations published by obesity medicine physicians treating patients on GLP-1 therapy.

What it won't do is pretend compounded semaglutide is FDA-approved. It isn't. Compounded semaglutide is prepared by a licensed compounding pharmacy under a clinician prescription, uses the same active ingredient as Wegovy and Ozempic, and has not been independently tested in randomized trials at the same scale as the branded products. The clinical evidence for the molecule itself comes from those branded trials. That distinction matters, and I'll stop belaboring it after this paragraph.

The Five-Step Titration and Why It Exists

The five-step escalation from the STEP-1 trial is the backbone of nearly every semaglutide protocol you'll encounter in clinical practice:

Weeks 1 through 4: 0.25 mg once weekly
Weeks 5 through 8: 0.5 mg
Weeks 9 through 12: 1.0 mg
Weeks 13 through 16: 1.7 mg
Week 17 onward: 2.4 mg (maintenance)

The structure isn't arbitrary. GLP-1 agonists slow gastric emptying. Your stomach needs time to recalibrate. Patients who skip steps reliably report worse nausea, worse vomiting, worse everything. Think of it like altitude acclimatization: you can physically drive to 14,000 feet in an afternoon, but your body will punish you for it.

For Ozempic (the diabetes-indicated formulation), the escalation is shorter and tops out lower: 0.25 mg for four weeks, then 0.5 mg, then 1.0 mg, with 2.0 mg available for glycemic control. Ozempic is not labeled for chronic weight management. The pharmacy supply situation in 2026 is more stable than the chaos of 2023 and 2024, but shifts still happen.

Reading the Dose List With Clinical Eyes

The five Wegovy doses (0.25, 0.5, 1.0, 1.7, and 2.4 mg, all subcutaneous, all weekly) each correspond to a titration step. Each branded pre-filled pen contains four weekly doses, which is how a one-month supply gets defined commercially.

Here's the thing most summaries gloss over: 0.25 mg is not a therapeutic dose for weight management. It exists purely for tolerability. The clinical response, the 14.9 percent mean weight loss from baseline at 68 weeks reported in STEP-1, was measured at the 2.4 mg maintenance dose. If you're at 0.25 mg and wondering why nothing seems to be happening, that's expected.

A question that comes up constantly: can 1.7 mg work as a long-term dose? For some patients, yes, particularly those who get persistent GI symptoms at 2.4 mg. But the full trial-level effect was measured at 2.4 mg. Settling at 1.7 mg is a legitimate clinical decision, not a failure, just a tradeoff your clinician should walk you through.

In compounded programs, the titration schedule is determined by the prescribing clinician and is typically informed by the Wegovy schedule above. The doses dispensed may be measured in milligrams rather than the pre-filled pen units used by branded products, which can be confusing if you're cross-referencing information from different sources.

Injection Logistics (The Boring Truth)

Semaglutide is a subcutaneous injection delivered into the abdomen, upper thigh, or upper arm. Rotate your sites week to week to avoid local irritation. Bring the medication to room temperature for fifteen to twenty minutes before injecting. Return it to refrigeration afterward unless the pharmacy specifically permits room-temperature storage for a defined window.

The injection itself takes seconds. Patients consistently say the anticipation is worse than the reality. Pick a fixed weekday and a consistent time. This makes adherence automatic and, just as importantly, helps you spot tolerability patterns. If you always inject Friday evening and always feel lousy Saturday morning, that's useful data for your clinician.

Three Reasons Doses Get Adjusted

Most dose adjustments trace back to one of three situations:

Intolerable GI symptoms that don't resolve within a week of a dose change. Some nausea at each step-up is normal. Nausea that makes you dread eating for seven straight days is not the plan.

Weight loss that's moving too fast. There's a threshold, roughly 1.5 to 2 percent of body weight per week, beyond which clinicians start worrying about lean mass loss, gallstone risk, and sustainability. Faster isn't always better.

A stalled response after months at maintenance. This sometimes prompts a different intervention entirely rather than pushing to a higher dose. The body adapts. The right answer at month eight may not be the same as the right answer at month three.

What the Trial Data Actually Show

The dosing framework comes from the STEP-1 trial: 2.4 mg weekly semaglutide versus placebo over 68 weeks, mean 14.9 percent weight loss from baseline in the active arm. STEP-3 added a structured lifestyle intervention to the same protocol and produced higher mean weight loss, which is the clearest evidence that the medication and lifestyle changes are additive, not interchangeable. SUSTAIN-6 and LEADER anchor the cardiovascular safety profile for the GLP-1 class. SELECT, completed in 2023, reported a 20 percent relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with established cardiovascular disease and overweight or obesity without diabetes.

Those numbers describe averages. Your individual result depends on genetics, metabolic history, adherence, and what you eat. (This is true of essentially every medication for every condition, but it bears repeating for a drug class that generates so much social media hype.)

Four Misconceptions That Keep Coming Up

"Compounded semaglutide has the same regulatory status as Wegovy." It does not. Compounding pharmacies operate under a different framework with different oversight. I said I'd stop belaboring this, but it matters enough to repeat once.

"Worse side effects mean the drug is working harder." Trial data don't support this. Patients with mild GI tolerability and patients who spent weeks miserable have both achieved meaningful weight loss in STEP-1 and STEP-3. Suffering is not a biomarker.

"The medication does all the work." STEP-3 showed that adding a structured lifestyle intervention produced greater mean weight loss than medication alone (STEP-1). My genuinely opinionated take: if you're on semaglutide and not paying attention to protein intake, you're leaving a significant amount of the outcome on the table.

"Stopping the medication resets you to zero." Not exactly, but STEP-4 documented partial weight regain over the 48 weeks after switching from active drug to placebo at week 20. The chronic biology of weight regulation reasserts itself without pharmacologic support, the same way blood pressure climbs back up when you stop an antihypertensive. This is a chronic condition, not a temporary fix.

Adjacent Reading

Where This Fits

This article is part of the Compounded Semaglutide Dosing and Protocols cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

What dose of compounded semaglutide is considered standard?

Compounded semaglutide protocols are written by the prescribing clinician and informed by the Wegovy escalation schedule used in STEP-1. The typical reference pattern is 0.25 mg weekly for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg, with the rate of titration adjusted to tolerability. Compounded preparations are not FDA-approved, and dosing is not standardized across pharmacies.

How does titration affect tolerability?

Slow titration is the single largest determinant of gastrointestinal tolerability in published semaglutide trials. The STEP-1 protocol used four-week steps specifically to allow gastric emptying changes to adapt gradually. Skipping or compressing steps is the most reliable way to make yourself miserable.

Can a clinician hold a dose without restarting titration?

Yes. Holding a current dose for an additional cycle to allow side effects to settle is a common clinical adjustment and does not require restarting the full titration schedule. That said, a multi-week gap (three or more weeks off the medication) may warrant stepping down before resuming the previous dose.

Is 1.7 mg a legitimate long-term dose?

For some patients, particularly those who experience persistent GI symptoms at 2.4 mg, 1.7 mg is a reasonable maintenance dose. The full trial-level effect was measured at 2.4 mg, so this is a clinical judgment call, not a one-size answer.

Does the injection site matter?

Abdomen, upper thigh, and upper arm are all acceptable. Rotating sites reduces the risk of localized irritation or lipodystrophy. Some patients report that abdominal injections are slightly less uncomfortable, but this is individual preference, not clinical guidance.

How long does it take to reach maintenance dose?

Following the standard STEP-1 schedule, patients reach the 2.4 mg maintenance dose at week 17. Some clinicians extend the timeline if tolerability is an issue, which is clinically appropriate and does not compromise long-term outcomes.

What happens if I miss a dose?

If fewer than five days have passed since the missed dose, take it as soon as you remember. If five or more days have passed, skip that dose and resume on your regular schedule. Do not double up. Discuss repeated missed doses with your clinician, as a prolonged gap may require a dose adjustment.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.